Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 2/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.36 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.33 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL559025 | 0.76 | PDE4A (0.42) | PDK1PDK2PDK3PDK4SCN8A | |
| SCHEMBL559960 | 0.75 | ALDH1A1 (0.45) | ALDH1A1MAPT | |
| SCHEMBL560648 | 0.70 | MAPK1 (0.43) | HTTALDH1A1MAPT | |
| SCHEMBL16971144 | 0.70 | MAPK1 (0.45) | ALDH1A1MAPT | |
| SCHEMBL31495022 | 0.67 | AR (0.43) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL13592935 | 0.66 | CXCR2 (0.46) | PDK1PDK2PDK3PDK4ALDH1A1 | |
| SCHEMBL9869447 | 0.66 | PDK1 (0.49) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL560675 | 0.65 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPT | |
| SCHEMBL11632309 | 0.65 | CHUK (0.38) | PDK1PDK2PDK3PDK4HTT | |
| SCHEMBL1800375 | 0.65 | PDK1 (0.42) | PDK1PDK2PDK3PDK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344028-B2 | Gamma-amino-butyric acid derivatives as GABAB receptor ligands | XENOPORT, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2012-02-09 | — | — | US | disclosed |
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | XENOPORT, INC. | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267676-A1 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | PDK1 2306/4885PDK2 1513/4885PDK3 2201/4885 |
| US-20120035139-A9 | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS | GABRB2, GABRB1, GABRB3 | PDK1 2306/4885PDK2 1513/4885PDK3 2201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.